Close
Close

Agios Pharmaceuticals, Inc. - Relapsed Pediatric AML

Partner

Not provided

Rare Disease

Relapsed Pediatric AML

Sponsor

Agios Pharmaceuticals, Inc.

Access Program Information

To provide access to ivosidenib monotherapy to patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase 1 (IDH1) mutation.

Contact
Locations

Free Newsletter